Current regulatory issues in cell and tissue therapy

Cytotherapy

Volumn 5, Issue 4, 2003, Pages 289-298

  Burger, Scott R ^a  

^a Advanced Cell and Gene Therapy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; BIOLOGICAL THERAPY; BONE MARROW TRANSPLANTATION; CLINICAL RESEARCH; CLINICAL TRIAL; CONTAMINATION; DISEASE TRANSMISSION; FOOD AND DRUG ADMINISTRATION; GENE REPLACEMENT THERAPY; GENE THERAPY; GOOD CLINICAL PRACTICE; HUMAN; IMMUNE SYSTEM; INFECTION; MEDICAL CARE; METABOLIC DISORDER; PHYSICAL DISEASE; QUALITY CONTROL; RELIABILITY; REVIEW; RISK; SAFETY; TISSUE REGENERATION; TISSUE REPAIR;

EID: 0142094685     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240310002324     Document Type: Review

References (36)

1. Report of the National Heart, Lung, and Blood Institute's Working Group on Cell-Based Therapies for Regenerative and Reparative Medicine: Vision, Scope, and Directions. National Institutes of Health, Bethesda, MD, 2002.
2. Stem Cells: Scientific Progress and Future Research Directions. National Institutes of Health, Bethesda, MD, 2001.
3. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Revs Immunol 2002;2:227-38.
4. Paul S, Calmels B, Acres RB. Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer. Curr Gene Ther 2002;2:91-100.
5. Down JD, White-Scharf ME. Reprogramming immune responses: Enabling cellular therapies and regenerative medicine. Stem Cells 2003;21:21-32.
6. US Pharmacopeia, General information chapter 1046, cell and gene therapy, Rockville, MD, 2002.
7. US Food and Drug Administration. National Organ Transplant Act of 1984. 42 CFR, Part 121.
8. National Marrow Donor Program. Standards. 18th Edition, 2002. www.marrow.org. visited 4th June 2003.
9. US Food and Drug Administration Current Good Manufacturing Practice for Blood and Blood Components. 21 CFR, Part 606, 1975.
10. US Food and Drug Administration. Establishment Registration and Product Listing for Manufacturers of Human Blood and Blood Products. 21 CFR, Part 607.
11. US Food and Drug Administration. Application of current statutory authorities to human somatic cell therapy products and gene therapy products. Fed Reg 1993;58:53248-51.
12. US Food and Drug Administration. Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs. 21 CFR Part 210.
13. US Food and Drug Administration. Current Good Manufacturing Practice for Finished Pharmaceuticals. 21 CFR Part 211.
14. US Food and Drug Administration. Proposed approach to regulation of cellular and tissue-based products. Docket 97N-0068, 1997. www.fda.gov/cber/gdlns/celltissue.pdf
15. Kessler DA, Siegel JP, Noguchi PD et al. Regulation of somatic-cell therapy and gene therapy by the Food and Drug Administration. N Engl J Med 1993;329:1169-73.
16. US Food and Drug Administration. Guidance for industry: Guidance for human somatic cell therapy and gene therapy. 1998. www.fda.gov/cber/gdlns/somgene.pdf
17. US Food and Drug Administration. Suitability determination for donors of human cellular and tissue-based products; Proposed rule (1999). Fed Reg 1999;64:52696-723. www.fda.gov/cber/rules/suitdonor.pdf
18. US Food and Drug Administration. Current good tissue practice for manufacturers of human cellular and tissue-based products; Inspection and enforcement; Proposed rule. Fed Reg 2001;66:1508-59. www.fda.gov/cber/rules/gtp010801pr.pdf
19. US Food and Drug Administration. Establishment registration and listing for manufacturers of human cellular and tissue-based products; Final rule. Fed Reg 2001;66:5447-69. www.fda.gov/cber/rules/frtisreg011901.pdf
20. International conference on harmonisation (ICH). E6 good clinical practice: Consolidated guideline. 1997. www.fda.gov/cber/guidelines.htm
21. US Food and Drug Administration. Guidance for industry: Validation of procedures for processing of human tissue intended for transplantation. 2002. www.fda.gov/cber/gdlns/tissval.pdf
22. Wells MA. Overview of FDA regulation of human cellular and tissue-based products. Food Drug Law J 1997;52:401-8.
23. Read EJ. The new regulatory environment for cellular therapy products: Challenges for academic-based manufacturing facilities. In: Smith Sibinga CT, de Ley L, editors. 'Cellular Engineering and Cellular Therapies'. Boston: Kluwer Academic Publishers: in press.
24. US Public Health Service Act 42 U.S.C., section 361.
25. Rowley SD. Current good manufacturing practices: Application to the processing of hematopoietic cell components. Cytotherapy 2000;2:59-62.
26. Keever-Taylor CA. Process control: Application to the cell processing laboratory. Cytotherapy 2000;2:63-73.
27. Burger SR. Design and operation of a cGMP cell engineering laboratory. Cytotherapy 2000;2:111-22.
28. McMannis JD, Champlin RE. Role of the GMP facility for adoptive immunotherapy. Cytotherapy 2002;4:329-31.
29. NIH Guidelines for research involving recombinant DNA molecules. Fed Reg April, 2002. www4.od.nih.gov/oba/rac/guidelines_02/NIH_Gdlnes_lnk_2002z.pdf
30. Foundation for the Accreditation of Cellular Therapya. Standards for Hematopoietic Progenitor Cell Collection, Processing, and Transplantation, 2nd edn. Omaha, NE: Foundation for the Accreditation of Cellular Therapy, 2002. www.unmc.edu/Community/fahct/Home_Page.htm
31. American Association of Blood Banks. Standards for Hematopoietic Progenitor and Cellular Therapies. 3rd edn. Bethesda, MD: American Association of Blood Banks, 2002. www.aabb.org
32. American Association of Tissue Banking. Standards for Tissue Banking. McLean, VA: American Association of Tissue Banking, 2001.
33. Clinical laboratory improvement amendments (CLIA): Laboratory requirements. Fed Reg 1988;42:493.
34. College of American Pathologists. Laboratory Accreditation Program. Laboratory Accreditation Manual. Northfield, IL: College of American Pathologists, 2001.
35. US Food and Drug Administration. Institutional Review Boards. 21 CFR Part 56.
36. FDA-CBER web site, www.fda.gov/cber